drug
abobotulinumtoxinA
Marketedupdated 4mo agoby Ipsen Biopharmaceuticals Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying abobotulinumtoxinA
- phase2A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
- phase2A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
- phase4Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A
- —Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
News(2)
- ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadershipThe ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.biopharma_dive · 2mo ago
- Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfrontPlus news on Alchemab, Scipher and Forte. 💉 Ipsen’s Dysport aces Phase 3 migraine trials: The biotech’s injectable neurotoxin met the primary endpoint of reducing monthly migraine days in two ...endpoints · 2mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that